Holen Sie sich die Stockscreener-App
1.69
0.60%
0.01
Schlusskurs vom Vortag:
$1.68
Offen:
$1.7
24-Stunden-Volumen:
78,073
Relative Volume:
1.02
Marktkapitalisierung:
$88.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.61M
KGV:
-13.48
EPS:
-0.1254
Netto-Cashflow:
$-3.10M
1W Leistung:
+7.64%
1M Leistung:
+13.42%
6M Leistung:
-38.77%
1J Leistung:
-40.91%
1-Tages-Spanne:
$1.65
$1.7285
1-Wochen-Bereich:
$1.57
$1.85
52-Wochen-Spanne:
$1.42
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Firmenname
Okyo Pharma Limited
Sektor
Branche
Telefon
-
Adresse
-
Compare OKYO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.69 | 88.69M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Piper Sandler | Overweight |
| 2025-12-08 | Eingeleitet | B. Riley Securities | Buy |
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
OKYO Forecast — Price Target — Prediction for 2027 - TradingView
OKYO Pharma advances toward Phase 3 FDA trialICYMI - Proactive financial news
OKYO's urcosimod gets FDA nod, moves to global phase 3 trial for NCP - Eyes On Eyecare
symbol__ Stock Quote Price and Forecast - CNN
OKYO Pharma secures positive FDA feedback for Urcosimod - grafa.com
Market movers: Alibaba, Broadcom, FuelCell Energy, OKYO Pharma... - Proactive financial news
OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain - Proactive financial news
OKYO Pharma advances urcosimod to Phase 3 trial for neuropathic corneal pain after positive FDA feedback - Pluang
OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain - Yahoo! Finance Canada
OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial - Investing.com
OKYO Pharma Secures FDA Backing to Advance Urcosimod into Global Phase 3 Trial for Neuropathic Corneal Pain - TipRanks
OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod to Treat Neuropathic Corneal Pain - marketscreener.com
OKYO Pharma (NASDAQ: OKYO) gets FDA feedback on pivotal Phase 3 NCP trial - Stock Titan
FDA feedback pushes OKYO Pharma into Phase 3 eye-pain study - Stock Titan
OKYO Pharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium - TipRanks
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium - The Manila Times
OKYO Pharma (OKYO) to join Piper Sandler 2026 Virtual Ophthalmology Symposium fireside chat - Stock Titan
OKYO Pharma CEO to speak at Piper Sandler virtual eye event July 9 - Stock Titan
OKYO Pharma announces participation in Piper Sandler 2026 Virtual Ophthalmology Symposium - Proactive financial news
Price to book forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Price to earnings forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to EBITDA forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to revenue forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to EBIT forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to EBIT forward of OKYO Pharma Limited – BOATS:OKYO - TradingView
OKYO Pharma Limited Actuals & Estimates (NASDAQ:OKYO) - TradingView
OKYO Pharma Ltd (OKYO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OKYO Pharma (OKYO) Edges Higher as Biotech Stock Tests Key Resistance Near $1.67Channel Breakout - dars.gov.et
OKYO Pharma And The Small-Cap Eye Care Story - Kalkine Media
OKYO Pharma Ltd (OKYO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OKYO Pharma Ltd (OKYO) Valuation: PE, PB & Fair Value Analysis - TradingKey
OKYO Pharma Ltd (OKYO) Institutional Confidence - TradingKey
OKYO Pharma Ltd (OKYO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OKYO Pharma Ltd (OKYO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OKYO Pharma Ltd (OKYO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKYO Pharma Ltd (OKYO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKYO (NASDAQ: OKYO) CMO Mantelli reports multi-year option holdings in Form 3 - Stock Titan
OKYO Pharma (OKYO) director awarded options on 3,500 common shares - Stock Titan
OKYO Pharma (OKYO) director awarded options for 6,500 shares at $1.85 - Stock Titan
Director at OKYO Pharma (NASDAQ: OKYO) receives stock options on 6,500 shares - Stock Titan
OKYO Pharma (OKYO) CFO receives grant of 40,000 options at $1.85 - Stock Titan
OKYO Pharma (OKYO) director adds 300,000-share grant via Panetta Partners - Stock Titan
OKYO Pharma Slips 1.85% as Shares Test Key Support LevelTrend Following Picks - newsline.com
OKYO Pharma (OKYO) Retreats Toward Support as Biotech Sector Faces HeadwindsATR Stop - dars.gov.et
OKYO Pharma (OKYO) director reports detailed stock option grants - Stock Titan
OKYO H2'25 Earnings: EPS estimate is (0.08) USD - TradingView
OKYO Pharma (OKYO) director discloses stock and option holdings - Stock Titan
[Form 3] OKYO Pharma Ltd Initial Statement of Beneficial Ownership - Stock Titan
OKYO Pharma Edges Lower, Holds Steady Near Key Support LevelStop Loss Guidance - newsline.com
OKYO Stock Price, Quote & Chart | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill
Finanzdaten der Okyo Pharma Limited-Aktie (OKYO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):